六神丸以毒攻毒治疗非小细胞肺癌临床研究

Clinical Research of Non-small Cell Lung Cancer Treated by Liushen Pill

目的:观察六神丸联合化疗治疗非小细胞肺癌(NSCLC)的临床疗效。方法:采用随机、对照的临床研究方法将60例患者分为观察组30例和对照组30例。观察组采用六神丸加GP(吉西他滨+顺铂)方案治疗,对照组单纯采用GP方案治疗;观察两组的疗效及对不良反应进行评价。结果:观察组和对照组有效率分别为50.00%(14/28)、46.51%(12/26),两组比较无显著性差异(P>0.05),但观察组在一般情况改善,咳嗽、咳痰、胸闷憋气3个症状改善,VEGF、CEA表达水平降低、免疫指标改善及减轻对白细胞的抑制、恶心呕吐方面与对照组有显著性差异(P<0.05)。结论:六神丸联合化疗在NSCLC治疗中有协同作用,能改善患者一般情况,提高生活质量,减轻化疗某些不良反应(恶心呕吐、白细胞减少)、降低化疗对患者免疫功能的影响,以毒攻毒是治疗非小细胞肺癌的有效方法之一。

Objective ： To observe the clinical efficacy of non - small cell lung cancer（NSCLC） treated by Liushen Pill combined with chemotherapy. Methods ：60 patients were randomly divided into two groups, 30 cases in the observed group and 30 ones in the control group. The observed group was treated by Liushen Pill combined with GP（ gemcitabine gemcitabine ＋ cisplatin） regi- men, the control group was treated with GP regimen only. The efficacy and adverse reactions were evaluated. Results ：The effective rate of the observed group and the control group were 50.00% （ 14/28 ）, 46.51% （12/26） respectively, the two groups showed no significant difference（P 〉 0. 05）, but the observed group improved the quality of life, alleviated some symptoms and adverse reactions, and even lowered the expression levels of VEGF and CEA （P 〈0. 05 ）. Conclusion ： These data show that the combina- tion of Liushen Pill and chemotherapy is an effective method in treatment of NSCLC.